All In MedTech

Device Trial Radar · NCT05108883

Risk Stratification Using Midregional Proadrenomedullin in the ED

IDEntifying pAtients With Suspicion of Infection in the ED Who Have Low Disease Severity Using Midregional Proadrenomedullin (MR-proADM) - Pivotal Study

Last checked: Nov 19, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingTitle says "pivotal". Randomized with 463 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

463

Actual

Start

Oct 14, 2021

Primary completion

Nov 7, 2023

Study completion Nov 7, 2023

Sponsor

Lead sponsor
Brahms AGNot on our public-company list
Sponsor type
Industry
First posted
Nov 5, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Emergency departments (ED) are becoming increasingly over-crowded, with patients facing prolonged waiting times. Therefore, a safe and rapid assessment that identifies patients with low severity that could be treated as outpatients is essential for improving the workflow within the ED. The rationale of this IDEAL+ study is to safely decrease the number of hospital admissions through identification of low risk patients with the biomarker MR-proADM. This will has already been tested in the IDEAL - pilot study and results should be confirmed with this IDEAL+ study.

Conditions

  • Patients Presenting With Suspicion of Infection to the ED

Interventions

  • MR-proADM KRYPTORDevice

    MR-proADM ≤ 0.87 nmol/L together with routine clinical evaluation identifies patients with low disease severity who do not need to be hospitalized

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of out-patients re-presenting to the EDTime frame: 5 days

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Hôpital Pitié-Salpêtrière, AP-HP.Sorbonne Université

    Paris, France

  • Policlinico Tor Vergata

    Roma, Italy

  • Hospital Santa Maria della Misericordia

    Udine, Italy

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.